http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Kyung Jin Eoh ) (검색결과 35 건)
- 무료
- 기관 내 무료
- 유료
-
-
Eoh, Kyung Jin,Kim, Ji Eun,Park, Hyung Seok,Lee, Seung-Tae,Park, Ji Soo,Han, Jung Woo,Lee, Jung-Yun,Kim, Sunghoon,Kim, Sang Wun,Kim, Jae Hoon,Kim, Young Tae,Nam, Eun Ji Korean Cancer Association 2018 Cancer Research and Treatment Vol.50 No.3
<P><B>Purpose</B></P><P>Next-generation sequencing (NGS) allows simultaneous sequencing of multiple cancer susceptibility genes and may represent a more efficient and less expensive approach than sequential testing. We assessed the frequency of germline mutations in individuals with epithelial ovarian cancer (EOC), using multi-gene panels and NGS.</P><P><B>Materials and Methods</B></P><P>Patients with EOC (n=117) with/without a family history of breast or ovarian cancer were recruited consecutively, from March 2016 toDecember 2016.GermlineDNAwas sequenced using 35-gene NGS panel, in order to identify mutations. Upon the detection of a genetic alteration using the panel, results were cross-validated using direct sequencing.</P><P><B>Results</B></P><P>Thirty-eight patients (32.5%) had 39 pathogenic or likely pathogenic mutations in eight genes, including <I>BRCA1</I> (n=21), <I>BRCA2</I> (n=10), <I>BRIP1</I> (n=1), <I>CHEK2</I> (n=2), <I>MSH2</I> (n=1), <I>POLE</I> (n=1), <I>RAD51C</I> (n=2), and <I>RAD51D</I> (n=2). Among 64 patients with a family history of cancer, 27 (42.2%) had 27 pathogenic or likely pathogenic mutations, and six (9.3%) had mutations in genes other than <I>BRCA1/2</I>, such as <I>CHECK2</I>, <I>MSH2</I>, <I>POLE</I>, and <I>RAD51C</I>. Fifty-five patients (47.0%) were identified to carry only variants of uncertain significance.</P><P><B>Conclusion</B></P><P>Using the multi-gene panel test, we found that, of all patients included in our study, 32.5% had germline cancer-predisposing mutations. NGS was confirmed to substantially improve the detection rates of a wide spectrum of mutations in EOC patients compared with those obtained with the <I>BRCA1/2</I> testing alone.</P>
-
( Kyung Jin Eoh ),( Jung-yun Lee ),( Sunghoon Kim ),( Sang Wun Kim ),( Jae Hoon Kim ),( Young Tae Kim ),( Ji Soo Park ),( Hyung Seok Park ),( Jeongwoo Han ),( Seung-tae Lee ),( Eun Ji Nam ) 대한산부인과학회 2016 대한산부인과학회 학술대회 Vol.102 No.-
목적: Next-generation sequencing (NGS) allows for simultaneous sequencing of multiple cancer susceptibility genes and may be more efficient and less expensive than sequential testing. We assessed the frequency of germline mutations among individuals with epithelial ovarian cancer (EOC) who received multigene panel test using NGS. 방법: Patients with EOC (n = 43) with/without family history of breast or ovarian cancer were recruited consecutively, from March 2016 to June 2016. Germline DNA was sequenced with a 35-gene NGS panel to identify mutations. Cross validation with direct sequencing was done, when genetic alteration was detected by the panel testing. 결과: Thirteen patients (30.2%) were identified to have pathogenic or likely pathogenic mutations in 6 genes, in BRCA1 (n = 6), BRCA2 (n = 3), CHEK2 (n = 1), BRIP1 (n = 1), POLE (n = 1), and RAD51C (n=1). Among the 18 patients with family history of cancer, 8 patients (44.4%) revealed to have pathogenic or likely pathogenic mutations, and 3 patients had mutations other than BRCA 1/2, such as CHECK2, POLE, and RAD51C. Eighteen patients (41.9%) were identified to carry variants of uncertain significance (VOUS) gene alterations. Lynch syndrome-related gene VOUS were identified in 5 individuals. 결론: Among sequential patients with ovarian cancer, 30.2% were found to have germline mutations in a gene that predisposes women to breast or ovarian cancer, using the panel. NGS substantially improved the detection rates of a wide spectrum of mutations in ovarian cancer patients, than does BRCA1/2 testing alone.
-
Marked impact of preeclampsia on cancer risk: A Nationwide Population-Based Cohort Study
( Kyung Jin Eoh ),( Eun Hwa Kim ),( Myeongjee Lee ),( Inkyung Jung ),( Young Tae Kim ) 대한산부인과학회 2022 대한산부인과학회 학술대회 Vol.108 No.-
Objective: To evaluate the cancer risk in a cohort of women with newly diagnosed preeclampsia. Methods: This nationwide, population-based retrospective cohort study used data from the 10-year claims database of the Korean National Health Insurance from January 2008 to December 2020. Patients diagnosed with preeclampsia between 2009 and 2013 were included; those who underwent appendectomy but were not diagnosed with preeclampsia during the study period served as controls. Participants diagnosed with cancer before enrollment were excluded. Cancer occurrence in both groups was identified and compared according to the diagnostic codes for different organ sites using the International Classification of Diseases, 10th revision. Results: In total, 42,380 patients with preeclampsia and 105,327 controls were analyzed, and the incidence rates of cancer were 333.1 and 376.97 per 100,000 person-years, respectively. Patients with preeclampsia had significantly increase cancers of gallbladder and biliary tract (hazard ration [HR], 5.492; 95% confidence interval [CI], 1.23124.501; p=0.0256), breast (HR, 1.168; 95% CI, 1.0181.340; p=0.0270), and thyroid (HR, 1.210; 95% CI, 1.0971.335; p=0.0020). In contrast, significantly decreased risk was observed in cancers of ovary (HR, 0.444; 95% CI, 0.2650.743; p=0.0001), and leukemia (HR, 0.364; 95% CI, 0.1640.806; p=0.0127). Conclusion: Preeclampsia had a significant impact on cancer risk of gallbladder and biliary tract, breast, thyroid, ovary, leukemia.
-
( Kyung Jin Eoh ),( Jung-yun Lee ),( Eun Ji Nam ),( Sunghoon Kim ),( Young Tae Kim ),( Sang Wun Kim ) 대한산부인과학회 2016 대한산부인과학회 학술대회 Vol.102 No.-
목적: To reduce toxicities of cisplatin-based intraperitoneal (IP) chemotherapy, cisplatin was substituted with carboplatin. We compared toxicities and long term survival outcomes of carboplatin- and cisplatin-based IP chemotherapy in advanced epithelial ovarian cancer. 방법: We conducted a retrospective study of patients receiving carboplatin-based (n=21, IP carboplatin AUC 5 on Day 1, IV paclitaxel 175mg/m2 on Day 2, and IP paclitaxel 60mg/m2 on Day 8) and cisplatin-based IP chemotherapy (n=16, IV paclitaxel 135mg/m2 on Day 1, IP cisplatin 100mg/m2 on Day 2, and IP paclitaxel 60mg/m2 on Day 8) after primary surgery for epithelial ovarian cancer (EOC) at Severance Hospital between Jan 2006 and Jun 2009. Toxicity data in a total of 210 cycles of IP chemotherapy were analyzed and survival data in each group was compared. 결과: There was significantly more grade 3 granulocytopenia (56.2%vs23.8%, p=0.044) and leukopenia (62.5%vs23.8%, p=0.018) in the IP cisplatin group. Patients treated with cisplatin based IP chemotherapy were more likely to suffer from chemotherapy related grade 2 or 3 nausea/vomiting (75.0%vs19.0%, p=0.001), abdominal pain (62.5%vs23.8%, p=0.018), hepatotoxicity (43.8%vs9.5%, p=0.016) and neuromuscular effects (56.2%vs19.0%, p=0.019). The proportion of patients who received 6 or more cycles in carboplatin based IP chemotherapy group was significantly higher than that in cisplatin based IP chemotherapy group (82.4%vs50.0%, p=0.049). Median progression-free survival (PFS) and overall survival (OS) in patients with FIGO stage 3, 4 were 19 and 50 in carboplatin group and 22 and 90 in cisplatin group. We found no significant between-group differences in PFS and OS (p=0.249 and 0.252). 결론: Carboplatin based IP chemotherapy is an acceptable alternative to cisplatin based IP chemotherapy for EOC. With the potential advantages of carboplatin based IP chemotherapy in the view of toxicity, carboplatin based IP chemotherapy may have an impact on the therapeutic strategy of EOC.
-
Eoh, Kyung Jin,Lee, So Hyun,Kim, Hee Jung,Lee, Jung-Yun,Kim, Sunghoon,Kim, Sang Wun,Kim, Young Tae,Nam, Eun Ji Elsevier 2018 Biochemical and biophysical research communication Vol.497 No.2
<P><B>Abstract</B></P> <P>MicroRNA-630 (miR-630) has been implicated in the development and progression of multiple cancers. The current study aimed to investigate the role of miR-630 in chemoresistant epithelial ovarian cancer. MiR-630 expression levels were detected in ovarian cancer cell line SKOV3 and paclitaxel-resistant SKOV3 (SKOV3-TR) via microarray and qRT-PCR. MiR-630 inhibitors and negative controls were transfected into SKOV3 and SKOV3-TR cells. Wound healing, invasion, chemosensitivity, and cell apoptosis assays were performed to determine proliferation and migration rates. Chemoresistant patient-derived xenograft (PDX) models were established and utilized to verify the effect of miR-630 on chemoresistant ovarian cancer. Inhibition of miR-630 decreased cell proliferation and enhanced the sensitivity of SKOV3-TR and SKOV3 cells to paclitaxel. In the chemosensitivity assay, we observed that the miR-630 inhibitor exhibited a synergistic effect with paclitaxel on SKOV3-TR cells. Inhibition was correlated with enhanced expression of apoptosis-related proteins. APAF-1 was predicted to be a potential target of miR-630. An <I>in vivo</I> PDX study showed that the miR-630 inhibitor sensitized chemoresistant ovarian cancer to paclitaxel. Thus, miR-630 inhibitor sensitizes chemoresistant epithelial ovarian cancer to chemotherapy by enhancing apoptosis. Our findings suggest that miR-630 might be a potential therapeutic target for chemotherapy-resistant ovarian cancer.</P> <P><B>Highlights</B></P> <P> <UL> <LI> We investigated the role of miR-630 in chemoresistant epithelial ovarian cancer. </LI> <LI> MiR-630 inhibition reduced proliferation and enhanced chemosensitivity <I>in vitro.</I> </LI> <LI> Inhibition was correlated with enhanced expression of apoptosis-related proteins. </LI> <LI> APAF-1 was predicted to be a potential target of miR-630. </LI> <LI> Inhibition sensitized chemoresistant ovarian cancer to paclitaxel <I>in vivo.</I> </LI> </UL> </P>
-
Eoh, Kyung Jin,Chung, Young Shin,Lee, So Hyun,Park, Sun-Ae,Kim, Hee Jung,Yang, Wookyeom,Lee, In Ok,Lee, Jung-Yun,Cho, Hanbyoul,Chay, Doo Byung,Kim, Sunghoon,Kim, Sang Wun,Kim, Jae-Hoon,Kim, Young Tae 대한암학회 2018 Cancer Research and Treatment Vol.50 No.3
<P><B>Purpose</B></P><P>Although the use of xenograft models is increasing, few studies have compared the clinical features or outcomes of epithelial ovarian cancer (EOC) patients according to the tumorigenicity of engrafted specimens. The purpose of this study was to evaluate whether tumorigenicity was associated with the clinical features and outcomes of EOC patients. </P><P><B>Materials and Methods</B></P><P>Eighty-eight EOC patients who underwent primary or interval debulking surgery from June 2014 to December 2015 were included. Fresh tumor specimens were implanted subcutaneously on each flank of immunodeficient mice. Patient characteristics, progression-free survival (PFS), and germline mutation spectra were compared according to tumorigenicity.</P><P><B>Results</B></P><P>Xenografts were established successfully from 49 of 88 specimens. Tumorigenicity was associated with lymphovascular invasion and there was a propensity to engraft successfully with high-grade tumors. Tumors from patientswho underwent non-optimal (residual disease ≥ 1 cm) primary orinterval debulking surgery had a significantly greater propensity to achieve tumorigenicity than those who received optimal surgery. In addition, patients whose tumors became engrafted seemed to have a shorter PFS and more frequent germline mutations than patients whose tumors failed to engraft. Tumorigenicity was a significant factor for predicting PFS with advanced International Federation of Gynecology and Obstetrics stage and high-grade cancers.</P><P><B>Conclusion</B></P><P>sTumorigenicity in a xenograft model was a strong prognostic factor and was associated with more aggressive tumors in EOC patients. Xenograft models can be useful as a preclinical tool to predict prognosis and could be applied to further pharmacologic and genomic studies on personalized treatments.</P>
-
Role of surgical therapy in the management of gestational trophoblastic neoplasia
( Kyung Jin Eoh ),( Young Shin Chung ),( Ga Won Yim ),( Eun Ji Nam ),( Sunghoon Kim ),( Sang Wun Kim ),( Young Tae Kim ) 대한산부인과학회 2015 Obstetrics & Gynecology Science Vol.58 No.4
Objective: To evaluate the role of adjuvant surgical procedures in the management of gestational trophoblastic neoplasia (GTN). Methods: In a retrospective review of medical records at the Severance Hospital, we identified 174 patients diagnosed with GTN between 1986 and 2006. Of the 174 patients, 129 (74%) were assigned to the nonmetastatic group, and 45 (26%) to the metastatic group; of the metastatic group patients, 6 were in the low-risk group and 39 were in the high-risk group. Thirtytwo patients underwent 35 surgical procedures as part of the GTN treatment. The procedures included hysterectomy, lung resection, craniotomy, uterine wedge resection, uterine suturing for bleeding, salpingo-oophorectomy, pretherapy dilatation and curettage, adrenalectomy, nephrectomy, and uterine artery embolization. Results: Of the 32 patients who underwent surgical procedures, 28 (87%) survived. Eleven patients underwent surgery for chemoresistant disease after receiving one or more chemotherapy regimens. Twelve patients underwent procedures to control tumor hemorrhage. Nine (81%) of 11 patients with chemoresistant disease survived, and 8 patients who underwent salvage surgery for chemoresistant disease received further chemotherapy. Of 21 patients who underwent hysterectomy, 19 (90%) achieved remission. All of three patients who had resistant foci of choriocarcinoma in the lung achieved remission through pulmonary resection. Conclusion: Adjuvant surgical procedures, especially hysterectomy and pulmonary resection for chemoresistant disease, as well as procedures to control hemorrhage, are pivotal in the management of GTN.
-
Single-port total laparoscopic hysterectomy in extremely huge uterus and safe in bag removal
( Kyung Jin Eoh ),( In Ok Lee ),( Young Shin Chung ),( Jung-yun Lee ),( Eun Ji Nam ),( Sunghoon Kim ),( Young Tae Kim ),( Jae Hoon Kim ),( Sang Wun Kim ) 대한산부인과학회 2016 대한산부인과학회 학술대회 Vol.102 No.-
목적: Teach a new procedure. 방법: The purpose of this video is to show single-port total laparoscopic hysterectomy in a patient with 6 months sized uterus and safe in bag morcellation techniques. A 1.5 cm sized skin incision on the umbilicus and punctured the fascia and peritoneum with a blade number 11. The incision size was same as women’s index finger diameter measuring smaller than 1.5cm. X-small sized Alexis wound retractor was inserted through the incision and then a surgical glove was attached to the wound retractor. I made small holes on the finger tips of the surgical glove and inserted 5 mm trocar into the 5th finger tip, 5 mm mini-port into the middle finger, 12 mm trocar into the thumb. And I made a small hole on the index finger and the hole was used as an entry port without trocar. Hysterectomy was started by ligating the utero-ovarian and round ligament with LigaSure. Then we further dissected the broad ligament and dissected the bladder while retroplexing the Rumi uterine manipulator. After tenting the bladder serosa I dissected the bladder with a monopolar cautery. And then I performed anterior colpotomy as early as possible to delineate the resection site. This anterior colpotomy indicates where to ligate the uterine vessels. After exposing the uterine vessels by dissecting the bladder and broad ligaments I ligate the uterine vessels with LigaSure. Then I completed colpotomy and then uterus was inserted in to a 3XL LapBag. The uterus was removed through the vagina with concealed cold knife morcellation in an endopouch. After removing the uterus, the vaginal cuff was closed intracorporeal continuous suture with Monosyn 1-0. 결과: We successfully completed single-port total laparoscopic hysterectomy in a patient with a extremely huge uterus. There was no specific complication. 결론: SP-TLH in patients with huge uterus was feasible in most cases using conventional laparoscopic instruments without articulated instruments.
-
( Kyung Jin Eoh ),( Minkyung Han ),( Eun Hwa Kim ),( Inkyung Jung ),( Young Tae Kim ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: Endometriosis is correlated with various cancers. However, the risk of cancer has not been established in a nationwide, population-based cohort of patients newly diagnosed with endometriosis. Methods: A retrospective population-based cohort study was performed using claims database of the Korean National Health Insurance from January 2008 to December 2018. Patients diagnosed with endometriosis between 2010 and 2013 were included; those who underwent appendectomy but were not diagnosed with endometriosis during the study period served as controls. None of these participants had been diagnosed with cancer prior to enrollment. ICD-10 cancer diagnoses were compared between these groups. Results: A total of 179,865 patients with endometriosis and 87,408 controls were analyzed, and the incidence rates of cancer were 644.3 and 543.8 per 100,000 person-years, respectively. Compared with controls, patients with endometriosis had a significantly increased overall risk of cancer (hazard ratio [HR], 1.34; 95% confidence interval [CI], 1.281.40; P < 0.001) after adjustment for age, insurance type, and comorbidities. They showed significantly increased risk of uterine (HR, 4.59; 95% CI, 3.565.91; P < 0.001), ovarian (HR, 2.51; 95% CI, 1.993.16; P < 0.001), cervical (HR, 1.84; 95% CI, 1.492.28; P < 0.001), breast (HR, 1.44; 95% CI, 1.311.58; P < 0.001), and thyroid (HR, 1.34; 95% CI, 1.241.45; P < 0.001) cancers. The median age at diagnosis was <50 years for all cancer types. Conclusion: Endometriosis was correlated with an increased risk of cancer, specifically uterine, ovarian, cervical, breast, and thyroid cancers. Patients with endometriosis should begin cancer screening early.
ScienceON연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
